Web Analytics

3 Latest Announced Rounds

  • $1,000,000
    Pre-Seed

    2 Investors

    Technology, Information and Internet
    Jan 30th, 2026
  • $23,000,000
    Series A

    4 Investors

    Software Development
    Jan 30th, 2026
  • $150,000,000
    Series B
    Technology, Information and Internet
    Jan 30th, 2026
$1,484.93M Raised in 39 Funding Rounds in the past 7 Days - View All

Funding Round Profile

T-CURX GmbH

start up
Germany - Würzburg, Bavaria
  • 18/12/2025
  • Series A
  • $20,000,000

T-CURX is a Biotech company, spun-out from the University Clinics Würzburg, Germany, developing first- and best-in-class personalized immunotherapies on the basis of CAR-T cells. CAR-T cells are a transformative, one-shot, chemotherapy-free targeted and personalized cancer treatment.
T-CURX has exclusive licenses for proprietary technologies and CAR-T product opportunities developed in the laboratory of Prof. M. Hudecek, Würzburg, Germany one of the leading European clinical CAR-T cell laboratories.

T-CURX leverages several cutting-edge CAR-T engineering technologies, including virus-free transposon based genetic engineering and a highly flexible and modular CAR format. This provides unparalleled flexibility, efficacy, safety, but also scalability for developing CAR-T cells at significantly lower costs than conventional lentivirus-based CAR-T cell manufacturing.


Related People